Furthermore, HER2+ breast cancer cells SKBR3 and JIMT were highly responsive to Talazoparib (IC50 at 0.04 μM for SKBR3 and 0.002 μM for JIMT1). This evidence concerns the gene ERBB2 and breast cancer.